Related Experiment Video
Updated: Dec 15, 2025
08:40
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
Published on: February 28, 2021
4.4K
Diroximel fumarate to treat multiple sclerosis
Y Wang1, P Bhargava2
1Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Drugs of Today (Barcelona, Spain : 1998)
|July 11, 2020
Summary
Diroximel fumarate (DRF), a new oral fumarate treatment for multiple sclerosis, is bioequivalent to dimethyl fumarate (DMF). This review examines DRF's pharmacology, pharmacokinetics, and clinical data, comparing it to the established DMF.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Therapeutics
Background:
- Multiple sclerosis (MS) is a chronic neurological disease.
- Oral fumarates, such as dimethyl fumarate (DMF), are established treatments for relapsing MS.
- Diroximel fumarate (DRF) is a newer oral fumarate recently approved for relapsing MS.
Purpose of the Study:
- To review the pharmacology, pharmacokinetics, metabolism, clinical studies, and drug safety of diroximel fumarate (DRF).
- To provide a comprehensive overview of DRF as a treatment for relapsing forms of multiple sclerosis.
- To compare DRF with dimethyl fumarate (DMF) based on available data.
Main Methods:
- Literature review of published studies on DRF and DMF.
- Analysis of pharmacological and pharmacokinetic data for DRF.
- Examination of clinical trial data (Phase III) for DRF's safety, tolerability, and efficacy.
Main Results:
- Diroximel fumarate (DRF) is bioequivalent to dimethyl fumarate (DMF), sharing the same active metabolite, monomethyl fumarate.
- DMF has a well-established profile of efficacy, safety, and tolerability.
- DRF has completed one Phase III study, with another ongoing, to further assess its clinical profile.
Conclusions:
- Diroximel fumarate (DRF) represents a new therapeutic option for relapsing multiple sclerosis.
- Understanding DRF's pharmacological and clinical characteristics is crucial for its application in MS treatment.
- Further studies will continue to elucidate the long-term safety and efficacy of DRF compared to DMF.
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
507
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
507
01:24Parkinson's Disease: Treatment
830
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
830
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
370
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
370
01:20Myasthenia Gravis: Overview and Treatment
2.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.5K
01:22Alzheimer's Disease: Treatment
659
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
659
01:29Drugs for Treatment of Ulcerative Colitis in IBD
349
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
349